AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZN) have been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is GBX 7,935.67 ($96.89).

Several analysts have recently issued reports on the company. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a £140 ($170.94) price target on shares of AstraZeneca in a research note on Friday, November 22nd. Finally, Berenberg Bank reiterated a “buy” rating and set a GBX 140 ($1.71) price target on shares of AstraZeneca in a research note on Monday, January 6th.

AstraZeneca Stock Performance

AZN opened at £109.82 ($134.09) on Friday. The company has a market cap of £170.22 billion, a PE ratio of 3,486.35, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The stock has a 50-day moving average of £104.72 and a 200-day moving average of £116.55. AstraZeneca has a 52-week low of GBX 9,461 ($115.52) and a 52-week high of £133.88 ($163.47). The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89.

Insider Buying and Selling

In other news, insider Tony Mok purchased 1,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($154.82) per share, with a total value of £190,200 ($232,234.43). Also, insider Pascal Soriot purchased 20,000 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was purchased at an average cost of £102.03 ($124.58) per share, with a total value of £2,040,600 ($2,491,575.09). 0.04% of the stock is owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.